nice pop in the last few days. "Pharmasset (VRUS - Cramer's Take - Stockpickr): This company develops antiviral drugs to treat hepatitis C, hepatitis B and HIV. The company's stock rocketed recently on positive data from a phase II study of its hepatitis C drug R7128 combined with interferon and ribavirin (the current standard of care for hepatitis C). R7128 is being developed in a partnership with Roche, and there has been some speculation that the Swiss drug maker could buy Pharmasset outright. " - thestreet.com